According to the report published by Allied Market Research, the global HIV drugs market was pegged at $30.89 billion in 2019 and is estimated to hit $36.49 billion by 2027, registering a CAGR of 3.8% from 2020 to 2027. The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends.
♦ Download Free Sample Report Here:
Human immunodeficiency virus (HIV) is one of the most challenging infectious diseases that affected around 39.6 million people globally by the end of 2018, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). Antiretroviral Therapy (ART) drugs are used for the treatment of HIV as they prevent the growth of the HIV virus.
As per the industry experts, long-term effect of COVID-19 outbreak is expected to be witnessed over the coming years. The outbreak has led to a situation of financial crisis in many countries. Moreover, in regions severely affected by COVID-19, HIV treatment procedures have been reduced to life or limb salvaging cases, owing to new government directives or hospital guidelines. Furthermore, all these factors are anticipated to impact the peripheral artery disease market as well in the future.
Disrupted of land & air transport services and failure of suppliers to deliver ARVs on time impacted the global market for HIV drugs negatively.
At the same time, rescheduling of HIV treatment measures has led to huge backlog of patients to deal with in the near future.
Nevertheless, as the lockdown has loosened off, private clinics that treat HIV are reopening yet again, and the market is projected to recover soon.
♦ Do Purchase Enquiry at:
Major Key Players Covered:
Key players in this market have adopted new product launch as the preferred strategy to expand their business. The key players profiled in this report include
- Boehringer Ingelheim International GmbH
- Merck & Co., Inc.
- Pfizer Inc.
- Gilead Sciences, Inc.
- GalaxoSmithKline plc.
- Johnson & Johnson,
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
Key findings of the study
- North America accounted for 48.40% market share in 2019, and is expected to maintain this trend over the forecast period.
- On the basis of medication class, the multi-class combination drugs segment is anticipated to grow at a CAGR of 4.1% from 2020 to 2027.
- The Asia-Pacific HIV drugs market is estimated to grow at a CAGR of 4.4% during the forecast period.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060